慧智 (6615)

About 慧智

Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M); and prenatal testing services, such as non-invasive prenatal screening, array, karyotyping, maternal serum screening for down syndrome, risk assessment for early/late-onset preeclampsia, folate metabolism genetic testing, congenital infection screening,carrier scan, thalassemia genetic testing, spinal muscular atrophy genetic testing, and fragile X syndrome genetic testing. It also provides baby genetic testing comprising sensorineural hearing loss genetic testing; congenital central hypoventilation syndrome genetic testing (CCHS); and congenital cytomegalovirus infection testing (CMV). In addition, the company offers cancer screening services, which includes human papillomavirus screening (HPV); and hereditary cancer testing services. Further, it develops precision medicine genetic testing; and offers testing services to patients and carriers with rare disorders. Sofiva Genomics Co.,Ltd. was founded in 2012 and is based in Taipei, Taiwan.

Headquarters: Taipei, TW · Website: https://www.sofivagenomics.com.tw

Frequently asked questions about 慧智 (6615)

What is 慧智 (6615)?

慧智 (6615) is a publicly traded company in the Healthcare sector (生技醫療業), listed on TPEx. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.